Probiotic Lactobacillus reuteri biofilms produce antimicrobial and anti-inflammatory factors

BMC Microbiology

Volumn 9, Issue , 2009, Pages

  Jones, Sara E ^a,b   Versalovic, James ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYPROPIONALDEHYDE; 3-HYDROXYPROPIONALDEHYDE; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; DRUG DERIVATIVE; GLYCERALDEHYDE; PROBIOTIC AGENT; PROPANE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BIOFILM; CELL LINE; HUMAN; ISOLATION AND PURIFICATION; LACTOBACILLUS REUTERI; METABOLISM;

ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; BIOFILMS; CELL LINE; GLYCERALDEHYDE; HUMANS; LACTOBACILLUS REUTERI; PROBIOTICS; PROPANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 62149117549     PISSN: 14712180     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-9-35     Document Type: Article

References (46)

1. Probiotics in man and animals. R Fuller, J Appl Bacteriol 1989 66 5 365 378 2666378
2. Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria. Report of the Joint Food and Agriculture Organization (FAO) of the United Nations/World Health Organization (WHO) Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. FAO/WHO, 2001 http://www.who.int/foodsafety/publications/fs-management/en/probiotics.pdf
3. Probiotics in prevention of IgE-associated eczema: a double-blind, randomized, placebo-controlled trial. TR Abrahamsson T Jakobsson MF Bottcher M Fredrikson MC Jenmalm B Bjorksten G Oldaeus, J Allergy Clin Immunol 2007 119 5 1174 1180 17349686
4. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. AV Shornikova IA Casas E Isolauri H Mykkanen T Vesikari, J Pediatr Gastroenterol Nutr 1997 24 4 399 404 9144122
5. Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. AV Shornikova IA Casas H Mykkanen E Salo T Vesikari, Pediatr Infect Dis J 1997 16 12 1103 1107 9427453
6. Effect of Lactobacillus challenge on Gardnerella vaginalis biofilms. S Saunders A Bocking J Challis G Reid, Colloids Surf B Biointerfaces 2007 55 2 138 142 17234391
7. Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study. F Savino E Pelle E Palumeri R Oggero R Miniero, Pediatrics 2007 119 1 e124 130 17200238
8. Increasing work-place healthiness with the probiotic Lactobacillus reuteri: a randomised, double-blind placebo-controlled study. P Tubelius V Stan A Zachrisson, Environ Health 2005 4 25 16274475
9. Lactobacillus reuteri tablets suppress Helicobacter pylori infection - a double-blind randomised placebo-controlled cross-over clinical study. K Imase A Tanaka K Tokunaga H Sugano H Ishida S Takahashi, Kansenshogaku Zasshi 2007 81 4 387 393 17695792
10. The Lactobacillus and Bifidobacterium microflora of the human intestine: composition and succession. G Reuter, Curr Issues Intest Microbiol 2001 2 2 43 53 11721280
11. Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract. N Valeur P Engel N Carbajal E Connolly K Ladefoged, Appl Environ Microbiol 2004 70 2 1176 1181 14766603
12. Oral microbial communities in sickness and in health. HF Jenkinson RJ Lamont, Trends Microbiol 2005 13 12 589 595 16214341
13. Airway biofilms: implications for pathogenesis and therapy of respiratory tract infections. H Kobayashi, Treat Respir Med 2005 4 4 241 253 16086598
14. Biofilms in the normal human large bowel: fact rather than fiction. RR Bollinger AS Barbas EL Bush SS Lin W Parker, Gut 2007 56 10 1481 1482 17872584
15. Microbial biofilms in the human gastrointestinal tract. S Macfarlane JF Dillon, J Appl Microbiol 2007 102 5 1187 1196 17448154
16. Microbial biofilms in the gut: visualization by electron microscopy and by acridine orange staining. D Palestrant ZE Holzknecht BH Collins W Parker SE Miller RR Bollinger, Ultrastruct Pathol 2004 28 1 23 27 14967595
17. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. A Swidsinski J Weber V Loening-Baucke LP Hale H Lochs, J Clin Microbiol 2005 43 7 3380 3389 16000463
18. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. EG Zoetendal A von Wright T Vilpponen-Salmela K Ben-Amor AD Akkermans WM de Vos, Appl Environ Microbiol 2002 68 7 3401 3407 12089021
19. Viscosity gradient within the mucus layer determines the mucosal barrier function and the spatial organization of the intestinal microbiota. A Swidsinski BC Sydora Y Doerffel V Loening-Baucke M Vaneechoutte M Lupicki J Scholze H Lochs LA Dieleman, Inflamm Bowel Dis 2007 13 8 963 970 17455202
20. Microbial biofilm communities in the gastrointestinal tract. S Macfarlane, J Clin Gastroenterol 2008 42 Suppl 3 Pt 1 S142 143 18806707
21. Modulation of gut mucosal biofilms. B Kleessen M Blaut, Br J Nutr 2005 93 Suppl 1 S35 40 15877893
22. Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. B Kleessen AJ Kroesen HJ Buhr M Blaut, Scand J Gastroenterol 2002 37 9 1034 1041 12374228
23. Fructans in the diet cause alterations of intestinal mucosal architecture, released mucins and mucosa-associated bifidobacteria in gnotobiotic rats. B Kleessen L Hartmann M Blaut, Br J Nutr 2003 89 5 597 606 12720580
24. Bacterial milieu and mucosal bacteria in ulcerative colitis. GT Macfarlane E Furrie S Macfarlane, Novartis Found Symp 2004 263 57 64 15669634
25. Genotypic and phenotypic studies of murine intestinal lactobacilli: species differences in mice with and without colitis. JA Pena SY Li PH Wilson SA Thibodeau AJ Szary J Versalovic, Appl Environ Microbiol 2004 70 1 558 568 14711688
26. Probiotic Lactobacillus spp. diminish Helicobacter hepaticus-induced inflammatory bowel disease in interleukin-10-deficient mice. JA Pena AB Rogers Z Ge V Ng SY Li JG Fox J Versalovic, Infect Immun 2005 73 2 912 920 15664933
27. Ecological behavior of Lactobacillus reuteri 100-23 is affected by mutation of the luxS gene. GW Tannock S Ghazally J Walter D Loach H Brooks G Cook M Surette C Simmers P Bremer F Dal Bello, Appl Environ Microbiol 2005 71 12 8419 8425 16332830
28. Production of 3-hydroxypropionaldehyde using a two-step process with Lactobacillus reuteri. Y Doleyres P Beck S Vollenweider C Lacroix, Appl Microbiol Biotechnol 2005 68 4 467 474 15682289
29. Lactobacillus fermentum attenuates the proinflammatory effect of Yersinia enterocolitica on human epithelial cells. JS Frick K Schenk M Quitadamo F Kahl M Koberle E Bohn M Aepfelbacher IB Autenrieth, Inflamm Bowel Dis 2007 13 1 83 90 17206643
30. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. S Sougioultzis S Simeonidis KR Bhaskar X Chen PM Anton S Keates C Pothoulakis CP Kelly, Biochem Biophys Res Commun 2006 343 1 69 76 16529714
31. Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport. S Menard C Candalh JC Bambou K Terpend N Cerf-Bensussan M Heyman, Gut 2004 53 6 821 828 15138208
32. Lactobacillus rhamnosus GG decreases TNF-alpha production in lipopolysaccharide-activated murine macrophages by a contact-independent mechanism. JA Pena J Versalovic, Cellular microbiology 2003 5 4 277 285 12675685
33. Building an intestine-architectural contributions of commensal bacteria. J Madara, N Engl J Med 2004 351 16 1685 1686 15483290
34. Human secretory immunoglobulin A may contribute to biofilm formation in the gut. RR Bollinger ML Everett D Palestrant SD Love SS Lin W Parker, Immunology 2003 109 4 580 587 12871226
35. Mucosal flora in inflammatory bowel disease. A Swidsinski A Ladhoff A Pernthaler S Swidsinski V Loening-Baucke M Ortner J Weber U Hoffmann S Schreiber M Dietel, Gastroenterology 2002 122 1 44 54 11781279
36. Modulation of bacterial growth by tumor necrosis factor-alpha in vitro and in vivo. JH Lee L Del Sorbo AA Khine J de Azavedo DE Low D Bell S Uhlig AS Slutsky H Zhang, Am J Respir Crit Care Med 2003 168 12 1462 1470 12958055
37. Immunoglobulin-mediated agglutination of and biofilm formation by Escherichia coli K-12 require the type 1 pilus fiber. PE Orndorff A Devapali S Palestrant A Wyse ML Everett RR Bollinger W Parker, Infect Immun 2004 72 4 1929 1938 15039312
38. Influence of probiotic vaginal lactobacilli on in vitro adhesion of urogenital pathogens to vaginal epithelial cells. G Zarate ME Nader-Macias, Lett Appl Microbiol 2006 43 2 174 180 16869901
39. Chemical characterization of an antimicrobial substance produced by Lactobacillus reuteri. TL Talarico WJ Dobrogosz, Antimicrob Agents Chemother 1989 33 5 674 679 2751282
40. Glycerol induces reuterin production and decreases Escherichia coli population in an in vitro model of colonic fermentation with immobilized human feces. V Cleusix C Lacroix S Vollenweider G Le Blay, FEMS microbiology ecology 2008 63 1 56 64 18028400
41. In vitro activity of vancomycin, quinupristin/dalfopristin, and linezolid against intact and disrupted biofilms of staphylococci. M El-Azizi S Rao T Kanchanapoom N Khardori, Ann Clin Microbiol Antimicrob 2005 4 2 15638934
42. Beneficial effect of auto-aggregating Lactobacillus crispatus on experimentally induced colitis in mice. I Castagliuolo F Galeazzi S Ferrari M Elli P Brun A Cavaggioni D Tormen GC Sturniolo L Morelli G Palu, FEMS Immunol Med Microbiol 2005 43 2 197 204 15681150
43. D-alanyl ester depletion of teichoic acids in Lactobacillus reuteri 100-23 results in impaired colonization of the mouse gastrointestinal tract. J Walter DM Loach M Alqumber C Rockel C Hermann M Pfitzenmaier GW Tannock, Environ Microbiol 2007 9 7 1750 1760 17564608
44. Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. K Mathee O Ciofu C Sternberg PW Lindum JI Campbell P Jensen AH Johnsen M Givskov DE Ohman S Molin, Microbiology (Reading, England) 1999 145 Pt 6 1349 1357 10411261
45. Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun. YP Lin CH Thibodeaux JA Pena GD Ferry J Versalovic, Inflamm Bowel Dis 2008 14 8 1068 1083 18425802
46. Human-derived probiotic Lactobacillus reuteri demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens. JK Spinler M Taweechotipatr CL Rognerud CN Ou S Tumwasorn J Versalovic, Anaerobe 2008 18396068